Year: 2025
Type: article
Abstract: Background: Actinic keratosis (AKs) is a common precancerous skin lesion that tipically develops in sun exposed areas and can progress into invasive squamous cell carcinomas.Moreover, sundamaged skin can lead to cosmetic concerns, psychological distress, and an increased risk of nonmelanoma skin cancers.Tirbanibulin 1% ointment is approved for the field treatment of Olsen grade I actinic keratosis of the face and scalp.In our experience, clearance of pigmented lesions resulted in a novel desirable side effect of this agent.Methods: We performed a prospective non-randomized study to assess the effectiveness and tolerability of tirbanibulin 1% ointment for the treatment of AKs and surrounding solar-damaged skin (field therapy), in a real-life setting.100 Patients were included: 79 males (79%) and 21 females (21%).Tirbanibulin, was applied daily for five consecutive days.A satisfactory response was defined by complete (100% reduction in the number of lesions) or partial clearance (75-99%) of treated AKs.Results: Total clearance of AKs was recorded in 52% of patients, while partial clearance was recorded in > 70% of lesions.An excellent tolerability profile and a high degree of satisfaction were observed.No treatment discontinuation due to adverse events was reported.Moreover, patients affected by pigmented actinic keratosis and solar lentigos experienced a marked clearance of this lesions as well as skin lightening effect and photorejuvenation.Conclusions: Our real-life experience confirms the effectiveness and safety of tirbanibulin 1% ointment for the treatment of AKs and surrounding solar-damed skin (field therapy).Furthermore, our study suggests the potential anti-aging and pigment-clearance efficacy of this agent.More studies are needed to understand the mechanisms causing this improvement.
Source: EJC Skin Cancer
Authors: M. Kuchner, T. Dirschka, P. Melzer, L. Schmitz
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,340
OpenAlex ID: W4409115201